NASDAQ:BSTC - BioSpecifics Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$43.0550 -0.33 (-0.76 %)
(As of 06/21/2018 03:11 AM ET)
Previous Close$43.38
Today's Range$42.5181 - $43.22
52-Week Range$38.05 - $53.77
Volume22,809 shs
Average Volume24,073 shs
Market Capitalization$309.21 million
P/E Ratio25.33
Dividend YieldN/A
Beta1.46
BioSpecifics Technologies logoBioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio18.34
Quick Ratio18.34

Price-To-Earnings

Trailing P/E Ratio25.33
Forward P/E Ratio20.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.44 million
Price / Sales11.30
Cash Flow$2.0434 per share
Price / Cash21.07
Book Value$9.39 per share
Price / Book4.59

Profitability

EPS (Most Recent Fiscal Year)$1.70
Net Income$11.32 million
Net Margins44.57%
Return on Equity18.92%
Return on Assets17.19%

Miscellaneous

Employees5
Outstanding Shares7,200,000

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by $0.05. The biopharmaceutical company had revenue of $7.09 million for the quarter, compared to analyst estimates of $7.97 million. BioSpecifics Technologies had a return on equity of 18.92% and a net margin of 44.57%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 brokerages have issued 1-year price objectives for BioSpecifics Technologies' shares. Their predictions range from $65.00 to $65.00. On average, they expect BioSpecifics Technologies' share price to reach $65.00 in the next year. View Analyst Ratings for BioSpecifics Technologies.

What are Wall Street analysts saying about BioSpecifics Technologies stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies stock:
  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (6/13/2018)
  • 2. HC Wainwright analysts commented, "We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M." (8/10/2017)

Who are some of BioSpecifics Technologies' key competitors?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Mr. Thomas L. Wegman, CEO, Pres, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 63)

Has BioSpecifics Technologies been receiving favorable news coverage?

Media stories about BSTC stock have been trending positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioSpecifics Technologies earned a daily sentiment score of 0.25 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.48%), Dimensional Fund Advisors LP (3.75%), Summit Trail Advisors LLC (3.25%), Elk Creek Partners LLC (2.29%), Eagle Asset Management Inc. (2.09%) and Prudential Financial Inc. (1.02%). Company insiders that own BioSpecifics Technologies stock include Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which institutional investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Elk Creek Partners LLC, GSA Capital Partners LLP, Prudential Financial Inc., Dimensional Fund Advisors LP, New York State Common Retirement Fund, Atlantic Trust Group LLC and UBS Group AG. View Insider Buying and Selling for BioSpecifics Technologies.

Which institutional investors are buying BioSpecifics Technologies stock?

BSTC stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Thomson Horstmann & Bryant Inc., Matarin Capital Management LLC, Eagle Asset Management Inc., Summit Global Investments, Millennium Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $43.0550.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $309.21 million and generates $27.44 million in revenue each year. The biopharmaceutical company earns $11.32 million in net income (profit) each year or $1.70 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (BSTC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.